Capricor Therapeutics Signs Binding Term Sheet with Nippon Shinyaku for European Expansion and Commercialization of Deramiocel for the Treatment of Duchenne Muscular Dystrophy
CAPRCapricor Therapeutics(CAPR) GlobeNewswire News Room·2024-09-17 21:15

-Capricor to Receive 15MillionEquityInvestmentata2015 Million Equity Investment at a 20% Premium, as well as 20 Million Upfront Payment upon Signing Definitive Agreement with up to 715MillioninPotentialMilestonesandaDouble−DigitPercentageofProductRevenue−−UpfrontPaymentandInvestmentExtendsCashRunwayinto2026−−PotentialMilestonesfromCombinedDistributionAgreementsNowTotalapproximately715 Million in Potential Milestones and a Double-Digit Percentage of Product Revenue- -Upfront Payment and Investment Extends Cash Runway into 2026- -Potential Milestones from Combined Distribution Agreements Now Total approximately 1.5 Billion- -Capricor Preparing to Meet with EMA to Discuss European Expansion for Deramiocel- SAN DIEGO, Sept. 17, 2024 ( ...